Novartis’ phase III QUARTZ study of new investigational inhaled combination treatment QMF149 meets primary and key secondary endpoints in patients with inadequately controlled asthma
Source: www.novartis.com
Novartis has announced the first study results from the phase III PLATINUM clinical development program assessing the safety and efficacy of QMF149, an investigational, once-daily, fixed-dose combination asthma treatment containing indacaterol acetate (IND – a long-acting beta agonist [LABA]) and mometasone furoate (MF – an anti-inflammatory [ICS]). Novartis reported the low dose QMF149 (indacaterol acetate and mometasone furoate) demonstrated both statistically significant and clinically meaningful improvements in lung function and asthma control compared to inhaled corticosteroid or ICS monotherapy.
